LAZZARONI, ELISA
LAZZARONI, ELISA
Dipartimento di Scienze Biomediche e Cliniche
Vaccinome landscape in nearly 620 000 patients with diabetes
2025 F. D'Addio, E. Lazzaroni, M. Elena Lunati, G. Preziosi, M. Ercolanoni, G. Turola, C. Marrocu, G. Cicconi, S. Sharma, S. Scarioni, L. Montefusco, I. Pastore, P. Silvia Morpurgo, A. Rossi, A. Gandolfi, C. Tinari, G. Rossi, M. BEN NASR, C. Loretelli, R. Maria Fiorina, B. Grassa, R. Terranova, L. Bucciarelli, C. Berra, D. Cereda, G. Zuccotti, C. Rosanna Borriello, P. Fiorina
Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide
2024 M.E. Lunati, V. Cimino, D. Bernasconi, A. Gandolfi, P.S. Morpurgo, C. Tinari, E. Lazzaroni, L. Baruffaldi, M. Muratori, L. Montefusco, I. Pastore, A. Rossi, I.G. Franzetti, F. Muratori, R. Manfrini, O.E. Disoteo, R. Terranova, P. Desenzani, A. Girelli, R. Ghelardi, F. D'Addio, M. Ben Nasr, C. Berra, F. Folli, L. Bucciarelli, P. Fiorina
The anti-inflammatory and immunological properties of SGLT-2 inhibitors
2023 G. Bendotti, L. Montefusco, I. Pastore, E. Lazzaroni, M.E. Lunati, P. Fiorina
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
2022 G. Bendotti, L. Montefusco, M.E. Lunati, V. Usuelli, I. Pastore, E. Lazzaroni, E. Assi, A.J. Seelam, B. El Essawy, J. Jang, C. Loretelli, F. D'Addio, C. Berra, M. Ben Nasr, G. Zuccotti, P. Fiorina
Dapagliflozin acutely improvMED/es kidney function in type 2 diabetes mellitus. The PRECARE study
2022 E. Lazzaroni, M.E. Lunati, L. Montefusco, I. Pastore, E. Chebat, V. Cimino, P.S. Morpurgo, M. Muratori, L. Plebani, A. Bolla, A. Rossi, L. Vallone, A. Gandolfi, C. Tinari, F. D'Addio, M.B. Nasr, C. Loretelli, C. Scaranna, R. Bellante, R. Manfrini, F. Muratori, I. Franzetti, E. Orsi, C. Gazzaruso, R. Ghelardi, P. Desenzani, S. Genovese, A. Girelli, F. Folli, C. Berra, P. Fiorina
Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves’ Orbitopathy
2022 I. Campi, G. Vannucchi, I. Muller, E. Lazzaroni, N. Currò, M. Dainese, B. Montacchini, D. Covelli, C. Guastella, L. Pignataro, L. Fugazzola, M. Arosio, M. Salvi
Efficacy profile and safety implications of very low dose Rituximab in patients with graves' orbitopathy
2021 G. Vannucchi, I. Campi, D. Covelli, N. Curro, E. Lazzaroni, A. Palomba, D. Soranna, A. Zambon, L. Fugazzola, I. Muller, C. Guastella, M. Salvi
Anti-diabetic drugs and weight loss in patients with type 2 diabetes
2021 E. Lazzaroni, M. Ben Nasr, C. Loretelli, I. Pastore, L. Plebani, M.E. Lunati, L. Vallone, A.M. Bolla, A. Rossi, L. Montefusco, E. Ippolito, C. Berra, F. D'Addio, G.V. Zuccotti, P. Fiorina
Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy.
2020 G. Lanzolla, G. Vannucchi, I. Ionni, I. Campi, F. Sileo, E. Lazzaroni, M. Marinò
SARS-CoV-2-related atypical thyroiditis
2020 I. Muller, D. Cannavaro, D. Dazzi, D. Covelli, G. Mantovani, A. Muscatello, E. Ferrante, E. Orsi, V. Resi, V. Longari, M. Cuzzocrea, A. Bandera, E. Lazzaroni, A. Dolci, F. Ceriotti, T.E. Re, A. Gori, M. Arosio, M. Salvi
Prevention of orbitopathy by oral or intravenous steroid prophylaxis in short duration Graves’ disease patients undergoing radioiodine ablation : A prospective randomized control trial study
2019 G. Vannucchi, D. Covelli, I. Campi, N. Curro, D. Dazzi, M. Rodari, G. Pepe, A. Chiti, C. Guastella, E. Lazzaroni, M. Salvi